Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

It's interesting that they're able to see immune responses in MSS CRC, a tumor that is notably "cold" from an immunological sense.

If they translate that into bona fide tumor responses, then it's going to be a big deal, since we saw with the early Neon Tx studies that there were no remissions that you could reasonably attribute to their neoantigen approach.


The lesson there, so far (and it's still early days), is that it doesn't seem to be enough to just generate immune responses. If ADXS's Lm-based approach is able to ramp the immune system to the point where we're seeing clinical remissions, then they have a very big deal scientifically. At this time, I'm prepared to see much the same as what Neon has seen, since there has been no publication of a clinical remission, either in the form of a presentation or a press release.

Not surprising, since it's phase 1, but hopefully ADXS will provide a positive surprise in the near future.